BlackRock Investment Management’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$13.1M Buy
306,232
+54,036
+21% +$2.2M 0.02% 933
2016
Q3
$10.4M Buy
252,196
+1,136
+0.5% +$47.6K 0.01% 988
2016
Q2
$10M Buy
251,060
+19,624
+8% +$706K 0.01% 959
2016
Q1
$7.79M Buy
231,436
+4,976
+2% +$155K 0.01% 1076
2015
Q4
$7.67M Buy
226,460
+2,648
+1% +$82.8K 0.01% 1099
2015
Q3
$6.66M Sell
223,812
-27,211
-11% -$851K 0.01% 1174
2015
Q2
$6.91M Buy
251,023
+33,382
+15% +$890K 0.01% 1246
2015
Q1
$5.48M Buy
217,641
+2,709
+1% +$64K 0.01% 1304
2014
Q4
$4.76M Sell
214,932
-950
-0.4% -$19.3K 0.01% 1393
2014
Q3
$4.38M Buy
215,882
+3,817
+2% +$76K 0.01% 1423
2014
Q2
$4.08M Buy
212,065
+9,047
+4% +$169K 0.01% 1541
2014
Q1
$3.82M Buy
203,018
+4,766
+2% +$92K 0.01% 1577
2013
Q4
$3.87M Buy
198,252
+20,256
+11% +$372K 0.01% 1535
2013
Q3
$2.93M Buy
177,996
+5,045
+3% +$81K ﹤0.01% 1668
2013
Q2
$2.59M Buy
+172,951
New +$2.53M ﹤0.01% 1669

Other funds holding IART

BlackRock Investment Management's IART Position: Q4 2016 in Review

BlackRock Investment Management increased its Integra LifeSciences (IART) stake by 21% in Q4 2016, buying an estimated $2.2M and bringing the position to 306,232 shares worth $13.1M. The position accounts for 0.02% of the portfolio, ranked #933.

BlackRock Investment Management first reported a position in IART in Q2 2013 and has held it in 15 quarters since. 223 funds tracked by Wall St. Rank hold IART as of Q4 2016.

  • BlackRock Investment Management held 306,232 shares of Integra LifeSciences worth $13.1M as of Q4 2016.
  • BlackRock Investment Management bought 54,036 Integra LifeSciences shares in Q4 2016, an estimated $2.2M.
  • Integra LifeSciences made up 0.02% of BlackRock Investment Management's portfolio in Q4 2016, its #933 holding.
  • BlackRock Investment Management first reported a position in Integra LifeSciences in Q2 2013 and has held it in 15 quarters since.
  • 223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.